Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses common skin side effects of EGFR inhibitors like cetuximab, noting their management remains based on clinical experience without strict therapy protocols, but provides no new clinical findings.

This study found that treatment with EGFR inhibitors or mitogen-activated kinase inhibitors may compromise the immune privilege of human scalp hair follicles, suggesting new directions for managing drug-induced folliculitis.

In this study, a combined therapy of nicotinamide and green tea polyphenols was reported to improve EGFR inhibitor-related skin toxicity and patient quality of life, suggesting it merits further investigation.

This study identified a novel microscopic "arrow sign" in hair root sheaths of patients on EGFR inhibitors, potentially aiding in diagnosing related hair changes and differentiating from fungal infections.

In a mouse model, this study found that LAM/TSC cells invaded the uterus and increased angiogenesis, while anti-EGFR antibody and rapamycin effectively reduced cell presence and blood vessel proliferation.

This study found that inhibiting EGFR and MEK in hair follicles may lead to a partial collapse of the immune privilege in the follicles and increased secretion of IL-33.

This study discusses two cases of acneiform skin eruptions associated with the use of the EGFR inhibitor ZD1839 in prostate cancer treatment, emphasizing the need for dermatologists to be aware of potential skin reactions.

This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.

This study found that lasers and light devices may alleviate recalcitrant skin side effects in cancer patients treated with EGFR inhibitors, offering an alternative for those who do not respond to traditional therapies.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

This study used in silico analysis to identify 4-[2-(4-nitrophenyl)ethylcarbamoyl]benzenesulfonyl as a potential inhibitor of the EGFR mutant associated with NSCLC, highlighting the need for further in vitro and in vivo validation.

This research observed that EGFR activity appears to maintain hair follicle quiescence and immune privilege, and its inhibition may lead to stem cell apoptosis and scarring alopecia during inflammation.

This study reported that in mouse models, deletion of EGFR resulted in stem cell hyper-proliferation followed by apoptosis, leading to scarring alopecia, and implicated EGFR's role in maintaining hair follicle quiescence and immune privilege during inflammation.

This study found that neutrophil-rich hair follicle inflammation caused by a monoclonal antibody targeting murine EGFR in mice involved TNFα and interleukin-1, suggesting these cytokines play a role in EGFR antibody-induced rashes in cancer patients.

This study in mice found that a monoclonal antibody targeting EGFR resulted in skin inflammation mediated by TNFα, suggesting potential pathways for addressing EGFR antibody-induced skin rash in cancer patients.

This study implicates EGFR as a critical regulator of immune privilege and stem cell quiescence in hair follicles, suggesting a link between EGFR inhibition and inflammation-driven hair loss during cancer therapy.

In this study, the HairCheck device was reported to accurately assess changes in hair density and diameter, suggesting its usefulness in monitoring alopecia progression and treatment response.

EGFR is essential for organized skin nerve growth and branching.

In this reported case, a 50-year-old man developed an acneiform rash, a common skin side effect of EGFR inhibitor therapy, after starting lapatinib for breast cancer; treatment with doxycycline and hydrocortisone cream led to significant improvement within one week.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

In this case report, a 65-year-old woman with non-small cell lung cancer experienced scarring alopecia with papulo-pustular lesions on the scalp due to gefitinib treatment, marking it as a rare instance of gefitinib-induced erosive pustular dermatosis of the scalp.

This study found that epidermal growth factor receptor inhibitors used in cancer treatment induce a distinct inflammatory response in hair follicles, marked by immune privilege collapse and upregulation of inflammatory pathways.

This article discusses the clinical manifestations and management strategies of skin side effects from epidermal growth factor receptor inhibitors, but reports no new clinical findings.

This study suggests that the dipeptide Pro-Ile has FGF18-like activity, can penetrate model human epidermis, and may have potential as a cosmetic ingredient for skin and hair regulation.

EGF receptors are crucial for skin cell growth and decrease with age.

This review discusses the role of the EGF receptor/ligand system in skin homeostasis and its implications for keratinocyte stem cells and reports no new clinical results.

This study found that TCDD significantly reduced EGF receptor binding in various animal models, linked to toxic symptoms like weight loss and developmental delays, with receptor phosphorylation persisting several days.

This study found that Pmab treatment may alter hair follicle growth cycles, leading to trichomegaly and hypertrichosis, but these effects do not correlate with other skin toxicities.